Drug Profile
ISIS CRPRx
Alternative Names: ISIS-329993; ISIS-CRP; ISIS-CRPRxLatest Information Update: 09 Aug 2019
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Isis Pharmaceuticals
- Class Antirheumatics; Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action C-reactive protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atrial fibrillation; Rheumatoid arthritis
Most Recent Events
- 09 Aug 2019 Discontinued - Phase-II for Atrial fibrillation in United Kingdom (SC)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 13 Aug 2015 Phase-II development for Atrial fibrillation is ongoing in United Kingdom